{
    "clinical_study": {
        "@rank": "110842", 
        "acronym": "MiCK Assay", 
        "arm_group": [
            {
                "arm_group_label": "Mesothelioma"
            }, 
            {
                "arm_group_label": "all cancer types"
            }
        ], 
        "biospec_descr": {
            "textblock": "Human cancerous tumor."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Testing Mayo Clinic cancer patients with the results being correlated with prior patient\n      therapy, performance status, and extent of disease."
        }, 
        "brief_title": "Validation of the MiCK Assay", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Mesothelioma, Small Cell Lung Cancer, NSCLC", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Mesothelioma", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted in two phases.\n\n      During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech\n      MiCK assay laboratory to determine the ease of sample acquisition, processing, transport,\n      and assay interpretation.\n\n      Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed\n      that the sample acquisition, processing, transport, and assay interpretation are\n      appropriate, we will proceed with the Demonstration Phase.\n\n      During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the\n      results will be correlated with prior patient therapy, performance status, and extent of\n      disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.\n\n        Exclusion Criteria:\n\n          -  patients that a sample cannot obtained for testing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01770665", 
            "org_study_id": "MAYO1000"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 18, 2014", 
        "link": {
            "url": "https://www.diatech-oncology.com/"
        }, 
        "location": {
            "contact": {
                "email": "karaus.mary@mayo.edu", 
                "last_name": "Mary Karaus", 
                "phone": "507-538-8472"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55901"
                }, 
                "name": "Mayo Validation Support Services 3050 Superior Drive NW"
            }, 
            "investigator": [
                {
                    "last_name": "Julian Molina, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Dennis Wigle, MD, PhD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Mayo Clinic Validation of the MiCK Assay", 
        "overall_contact": {
            "email": "karaus.mary@mayo.edu", 
            "last_name": "Mary Karaus", 
            "phone": "507-538-8472"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Mary Karaus", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Mayo Clinic IRB", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete response and survival", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01770665"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "DiaTech Oncology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DiaTech Oncology", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "1 Year", 
        "verification_date": "January 2013"
    }
}